CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2017 St. Gallen International Breast Cancer Conference
Oncology Conference Multimedia
View more videos >>
Dr. Janni on Reducing Adverse Events of HER2-Targeted Treatment in Breast Cancer
Dr. Curigliano Discusses Immunotherapy in Breast Cancer
Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer
Oncology Conference Articles
Neoadjuvant Therapy Fundamental in TNBC and HER2+ Breast Cancer
Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.
Age, Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer
Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.
Expert Examines Clues to Deploying Immunotherapy in Breast Cancer
Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.
Big Data May Guide Future Treatment Decisions
The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.
CDK4/6 Inhibitors Changing Practice in Advanced Breast Cancer
Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.
Expert Discusses Promise of Immunotherapy in TNBC
Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.
Combination Approaches Combat Resistance to Endocrine Therapy in HR+ Breast Cancer
Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.
Ribociclib Response Unaffected by Prior Treatment
Updated findings from the MONALEESA-2 trial demonstrated that the response to ribociclib (Kisqali) in postmenopausal women with hormone-receptor-positive/HER2-negative advanced or metastatic breast cancer was unaffected by either prior endocrine treatment or prior chemotherapy.
Combinations Show Promise in Overcoming Resistance to HER2-Targeting Therapy
C. Kent Osborne, MD, discusses current strategies for overcoming resistance to HER2-targeting agents in early breast cancer today.
FDA Approval in NSCLC, Priority Review in SCLC, 2018 SABCS Highlights, and More
Jagannath Discusses Building on the Biology of Multiple Myeloma
Adjuvant Pembrolizumab Approved in EU for Stage III Melanoma
FDA Approves Trastuzumab Biosimilar for HER2+ Breast Cancer
Expert Reflects on Recent Pivotal Data in RCC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.